Short Course Regimens for Treatment of PKDL (Sudan)

NCT03399955 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

110

Enrollment

OTHER

Sponsor class

Conditions

PKDL - Post-Kala-Azar Dermal Leishmanioid

Interventions

DRUG: Paromomycin
DRUG: Ambisome
DRUG: Miltefosine

Sponsor

Drugs for Neglected Diseases